
Results
4
Companies which are more than 50% undervalued based on analyst price target.
4 companies
Selvita
Market Cap: zł576.4m
Provides drug discovery, drug development, and contract testing services in Poland.
SLV
zł31.40
7D
-0.6%
1Y
8.3%
Ryvu Therapeutics
Market Cap: zł350.5m
A clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally.
RVU
zł15.16
7D
9.5%
1Y
-52.6%
Molecure
Market Cap: zł124.4m
A biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland.
MOC
zł6.04
7D
8.1%
1Y
0%
Poltreg
Market Cap: zł108.9m
A biotechnology company, researches and develops therapies for autoimmune diseases.
PTG
zł18.40
7D
-3.2%
1Y
-43.7%